12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Latanoprostene bunod: Phase III started

Bausch + Lomb began the double-blind, international Phase III LUNAR trial to compare once-daily latanoprostene bunod vs. twice-daily timolol for 3 months in about 393 patients with glaucoma and ocular hypertension. Bausch +...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >